Gentris Corp. has expanded its genomic biomarker services, adding multiple technology platforms to its 24,000-sq.-ft., CLIA-certified, GLP-compliant lab. Gentris has integrated the Affymetrix GCS3000, Sequenom MassArray, and LifeTech Ion Torrent technologies to identify polymorphisms involved in drug response and adverse drug events as well as determining somatic mutations in cancer. 
 
Affymetrix DMET Plus analysis allows drug developers to understand how variations in drug metabolism enzymes and drug transporters between patients affects adverse drug responses and treatment efficacy. Sequenom’s MassArray allows for customized design for multiplex panels of genes for clinical trials. Additionally, the LifeTech’s Ion Torrent Personal Genome Machine (PGM) for next generation sequencing allows for rapid sequencing of large areas of the genome, which can identify both common and rare variations to better predict the safety and efficacy of new drugs.